The combination of etoposide and cisplatin in non-small-cell lung cancer (NSCLC)

Annals of Oncology

Volumn 10, Issue SUPPL. 5, 1999, Pages

  Ardizzoni, A ^a   Antonelli, G ^a   Grossi, F ^a   Tixi, L ^a   Cafferata, M ^a   Rosso, R ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

Advanced disease; Chemotherapy; Cisplatin; Etoposide; Non small cell lung cancer

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GEMCITABINE; METHOTREXATE; MITOMYCIN; NAVELBINE; PACLITAXEL; PROCARBAZINE; VINBLASTINE;

CANCER COMBINATION CHEMOTHERAPY; CLINICAL TRIAL; CONFERENCE PAPER; DRUG COST; DRUG EFFICACY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0032692489     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/10.suppl_5.S13     Document Type: Conference Paper

References (34)

1. Non-Small-Cell Lung Cancer Collaborative Group. Chemotherapy in non-small-cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomized clinical trials. BMJ 1995; 311: 899-908.
2. Thatcher N, Ranson M, Lee SM et al. Chemotherapy in non-small-cell lung cancer. Ann Oncol 1995; 6: S83-95.
3. Schabel FM Jr, Trader MW, Laster WR et al. Cis-dichlorodiamine-platinum (II): Combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979; 63: 1459-73.
4. Goldhirsch A, Joss RA, Cavalli F et al. Cis-dichlorodiammine-platinum (II) and VP16-213 combination chemotherapy for non-small-cell lung cancer. Med Pediatr Oncol 1981; 9: 205-8.
5. Longeval E, Klastersky J. Combination chemotherapy with cisplatin and etoposide in bronchogenic squamous cell carcinoma and adenocarcinoma. A study by the EORTC Lung Cancer Working Party (Belgium). Cancer 1982; 50: 2751-6.
6. Veronesi A, Zagonel V, Santarossa M et al. Cisplatinum and etoposide combination chemotherapy of advanced non-oat cell bronchogenic carcinoma. Cancer Chemother Pharmacol 1983; 11:35-7.
7. Mitrou PS, Graubner M, Berdel WE et al. Cisplatinum (DDP) and VP16-213 (etoposide) combination chemotherapy for advanced non-small-cell lung cancer: A phase II clinical trial. Eur J Cancer Clin Oncol 1984; 20: 347-51.
8. Ardizzoni A, Canobbio L, Pronzato P et al. Etoposide and high-dose cisplatin in good-risk patients with advanced squamous cell carcinoma and adenocarcinoma of the lung. Cancer Treat Rep 1986; 70: 891-2.
9. Klastersky J, Sculier JP, Ravez P et al. A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol 1986; 4: 1780-6.
10. Gralla RJ, Casper ES, Kelsen DP et al. Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: A randomized trial investigating two dosage schedules. Ann Intern Med 1981; 95: 414-20.
11. Krook JE, Jett JR, Little C. A phase I-II study of sequential infusion VP-16 and cisplatin therapy in advanced lung cancer. Am J Clin Oncol 1989; 12: 114-7.
12. Goldberg RM, Jett JR, Therneau TM et al. Bolus versus infusion regimens of etoposide and cisplatin in treatment of non-small-cell lung cancer: A study of North Central Cancer Treatment Group. J Natl Cancer Inst 1990; 82: 1899-903.
13. Splinter T, Kok T, Kho S et al. A multicenter phase II trial of cisplatin and oral etoposide (VP-16) in inoperable non-small-cell lung cancer. Semin Oncol 1986; 13: 97-103.
14. Planting A, Kho S, van der Burg M et al. A phase II study of weekly high-dose cisplatin combined with oral etoposide in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 1997; 40: 347-52.
15. Lee JS, Scott C, Komaki R et al. Concurrent chemoradiation therapy with oral etoposide and cisplatin for locally advanced inoperable non-small-cell lung cancer: Radiation Therapy Oncology Group Protocol 91-06 J Clin Oncol 1996; 14: 1055-64.
16. Klastersky J, Sculier JP, Nicaise C et al. Combination chemotherapy with cisplatin, etoposide and vindesine in non-small-cell carcinoma: A clinical trial of the EORTC Lung Cancer Working Party. Cancer Treat Rep 1983; 67: 727-30.
17. Bertrand M, Multhauf P, Presant C et al. Phase II trial of etoposide, vincristine and high-dose cisplatin in advanced non-small cell lung cancer. Cancer Treat Rep 1985; 69: 1335-6.
18. Osoba D, Rusthoven JJ, Turnbull KA et al. Combination chemotherapy with bleomycin, etoposide and cisplatin in metastatic non-small-cell lung cancer. J Clin Oncol 1985; 3: 1478-85.
19. Ardizzoni A, Fusco V, Gulisano M et al. Etoposide, ifosfamide, and cisplatin in the treatment of advanced non-small-cell lung cancer. Cancer Treat Rep 1987; 71: 1311-2.
20. Dhingra HM, Valdivieso M, Carr DT et al. Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 1985; 3: 176-83.
21. Paccagnella A, Favaretto A, Brandes A et al. Cisplatin, etoposide, and ifosfamide in non-small-cell lung carcinoma. A phase II randomized study with cisplatin and eetoposide as the control arm. Cancer 1990; 65: 2631-4.
22. Joss RA, Alberto P, Obrecht JP et al. Combination chemotherapy for non-small-cell lung cancer with doxorubicin and mitomycin or cisplatin and etoposide. CancerTreat Rep 1984; 68: 1079-84.
23. Ruckdeschel JC, Finkelstein DM, Ettinger DS et al. A randomized trial of the four most active regimens for metastatic non-small-cell lung cancer. J Clin Oncol 1986; 4: 14-22.
24. Veronesi A, Magri MD, Tirelli U et al. Chemotherapy of advanced non-small-cell lung cancer with cyclophosphamide, adriamycin, methotrexate, and procarbazine versus cisplatin and etoposide. A randomized study. Am J Clin Oncol 1988; 11: 566-71.
25. Paccagnella A, Brandes A, Pappagallo GL et al. Cisplatin plus vindesine versus cisplatin plus VP16 versus doxorubicin plus cytoxan in non-small-cell carcinoma of the lung. A randomized study. Tumori 1986; 72: 417-25.
26. Rosso R, Ardizzoni A, Salvati F et al. Etoposide vs. etoposide and cisplatin in the treatment of advanced non-small-cell lung cancer: A FONICAP randomized study. Semin Oncol 1988; 15: 49-51.
27. Crinò L, Tonato M, Darwish S et al. A randomized trial of three cisplatin-containing regimens in advanced non-small-cell lung cancer (NSCLC): A study of the Umbrian Lung Cancer Group. Cancer Chemother Pharmacol 1990; 26: 52-6.
28. Klastersky J, Sculier JP, Bureau G et al. Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. J Clin Oncol 1989; 7: 1087-109.
29. Crinò L, Clerici M. Figoli F et al. Chemotherapy of advanced non-small-cell lung cancer: A comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (GOIRC). Ann Oncol 1995; 6: 347-53.
30. Manegold C, Bergman B, Chemaissani A et al. Single-agent gemcitabine versus cisplatin etoposide: Early results of a randomised phase II study in locally advanced or metastatic non-small-cell lung cancer. Ann Oncol 1997; 8: 525-9.
31. Perng RP, Chen YM, Ming-Liu J et al. Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 1997; 15: 2097-102.
32. Lopez Cabrerizo MP, Cardenal F, Artal A et al. Gemcitabine plus cisplatin versus etoposide plus cisplatin in advanced non-small-cell lung cancer: A randomized trial by the Spanish Lung Cancer Group. Lung Cancer 1997; 18 (Suppl 1): 10.
33. Bonomi P, Kyungmann K, Kusler J et al. Cisplatin etoposide vs. paclitaxel-cisplatin-G-CSF vs. paclitaxel-cisplatin in non-small-cell lung cancer. An ECOG phase III trial. Oncology 1997; 11 (Suppl 3): 9-10.
34. Earle C, Evans WK, Will BP, Berthelot J-M et al. Comparison of the costs, toxicity, and inconvenience of different chemotherapy regimens for advanced non-small-cell lung cancer. Lung Cancer 1997; 18 (Suppl 1): 26.